Company: BFRG
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001641172-25-009946
Chunk: 15

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Item 1
Chunk 15
---
 Agreement whereby the Company gained access to
certain improvements including additional patents and know-how in exchange for a series of payments totaling $275,000. The first of these
payments for $75,000 was paid in July 2023 and the remaining payments of $75,000, $75,000, and $50,000 are due in years 2025, 2026 and
2027, respectively. The amendment also reduced the 2023 minimum annual royalty payment to $60,000, all other financial terms remain the
same.

As
of March 31, 2025, all minimum annual royalty payments through 2024 have been paid, the Company has accrued $75,000 of the $300,000 minimum
annual royalty for 2025, and the Company has accrued $45,000 of the $75,000 annual license fee due in June 2025. The Company assessed
whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable.
The Company expensed the license fee and will expense development costs until commercial viability is likely.

George
Washington University - Beta2-spectrin siRNA License

In
January 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (“GWU”)
for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma. The license
covers methods claimed in three U.S. and worldwide patent applications, and also includes use of this approach for treatment of obesity,
non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

In
consideration of the rights granted to the Company under the license agreement, the Company paid GWU a $20,000 license initiation fee
in 2022. Under the terms of the license agreement, GWU will be entitled to a three percent (3%) royalty on net sales subject to quarterly
minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company
sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent
costs. The sublicense and assignment fee amounts decline as the Company advances the clinical development of the licensed technology.
The license agreement also contains milestone payments for clinical development through the approval of a new drug application (“NDA”)
by the U.S. Food and Drug